SAR441344 + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sjögren's Syndrome
Conditions
Sjögren's Syndrome, Sjogren's Syndrome
Trial Timeline
Nov 12, 2020 → Feb 9, 2024
NCT ID
NCT04572841About SAR441344 + Placebo
SAR441344 + Placebo is a phase 2 stage product being developed by Sanofi for Sjögren's Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT04572841. Target conditions include Sjögren's Syndrome, Sjogren's Syndrome.
What happened to similar drugs?
0 of 8 similar drugs in Sjögren's Syndrome were approved
Approved (0) Terminated (1) Active (7)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04572841 | Phase 2 | Completed |
Competing Products
20 competing products in Sjögren's Syndrome